Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

China's State FDA Gets WHO Nod For Vaccine Regulatory System; Opens Global Market For Chinese Vaccine Makers

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - China's State FDA now complies with international standards for vaccine regulation and Chinese vaccine makers are eligible to apply for World Health Organization prequalification of vaccine products, WHO announced March 1, the same day that China implemented its newly revised good manufacturing practices (GMP) guidelines

You may also be interested in...



A Closer Look: With Only 60% Of China’s Sterile Drug Makers Passing New GMP Standard, What’s Next?

Only 60% of sterile drug manufacturers passed the new GMP standard in China, as smaller companies chose to quit the market.

China Releases New, Stricter Vaccine GCP Regulations

China FDA releases new vaccine good clinical practices regulations that detail responsibilities of sponsors, clinical research organizations, sites, investigators and ethics committees.

First Made-In-China Vaccine Gets WHO-Prequalification Setting The Stage For A New Global Player

China’s first World Health Organization prequalified vaccine marks a milestone in the country’s efforts to build on its massive internal demand. It also places the spotlight on other local vaccine producers that hope to repeat the success of the Chengdu Institute of Biological Products.

Related Content

Latest News
UsernamePublicRestriction

Register

SC077587

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel